Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled Study

2010 ◽  
Vol 87 (5) ◽  
pp. 609-613 ◽  
Author(s):  
J Morganroth ◽  
H Lepor ◽  
L A Hill ◽  
W Volinn ◽  
G Hoel
Keyword(s):  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Healthy Men ◽  
Adrenoceptor Antagonist

Effects of 2 wk of GH administration on 24-h indirect calorimetry in young, healthy, lean men

2005 ◽  
Vol 289 (6) ◽  
pp. E1030-E1038 ◽  
Author(s):  
Mette Hansen ◽  
Rikke Morthorst ◽  
Benny Larsson ◽  
Allan Flyvbjerg ◽  
Michael Højby Rasmussen ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Indirect Calorimetry ◽  
Substrate Oxidation ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Healthy Men ◽  
Healthy Humans ◽  
Hormone Administration ◽  
Over Time

The present study was designed as a randomized, double-blind placebo (Plc)-controlled study to determine the effect of 2 wk of growth hormone administration (GH-adm.) on energy expenditure (EE) and substrate oxidation in healthy humans. Sixteen young healthy men were divided into two groups. The study consisted of two 24-h measurements (indirect calorimetry), separated by 2 wk of either Plc or GH injections (6 IU/day). At baseline, no significant differences were observed between the two groups in any of the measured anthropometric, hormonal, or metabolic parameters, neither did the parameters change over time in the Plc group. GH-adm. resulted in a 4.4% increase in 24-h EE ( P < 0.05) and an increase in fat oxidation by 29% ( P < 0.05). However, a decrease in the respiratory quotient was only observed in the postabsorptive phase after an overnight fast (0.84 ± 0.1 to 0.79 ± 0.1, P < 0.05). Furthermore, lean body mass (LBM) was increased by GH-adm. only [62.8 ± 2.5 kg (baseline) vs. 64.7 ± 2.4 kg (after), P < 0.001]. In conclusion, GH-adm. increases 24-h EE, which may be partly explained by increased LBM. Furthermore, GH-adm. stimulates fat combustion, especially in the postabsorptive state.

884: Phase I, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Investigate the Safety, Tolerability, and Pharmacokinetics of DA-8159

2004 ◽  
Vol 171 (4S) ◽  
pp. 234-234 ◽  
Author(s):  
Harin Padma-Nathan ◽  
Jae Seung Pacik ◽  
Byoung Ok Ahn ◽  
Kyung Koo Kang ◽  
Mi Young Bahng ◽  
...  
Keyword(s):  
Phase I ◽  
Controlled Study ◽  
Healthy Male ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Male Subjects
Sign in / Sign up

Export Citation Format

Share Document